

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Adobe Acrobat - [EP1406692.pdf]

File Edit Document Tools View Window Help

Takes the place of EP1406692 (art.158 of the EPC)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2002 (14.11.2002)

(10) International Publication Number
WO 02/089904 A2

(51) International Patent Classification⁷: A61N 114th Avenue Northwest, Coon Rapids, MN 55433 (US).
STROM, James; 3740 McCracken Lane, Arden Hills, MN 55112 (US).

(21) International Application Number: PCT/US02/08889

(22) International Filing Date: 20 March 2002 (20.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/850,331 7 May 2001 (07.05.2001) US

(71) Applicant: MEDTRONIC, INC. [US/US]; 710 Medtronic Parkway LC340, Minneapolis, MN 55432 (US).

(72) Inventors: FARLEY, Mary, A; 3835 Susan Lane, Min-

(74) Agents: WOLDE-MICHAEL, Girma, et al.; Medtronic, Inc., 710 Medtronic Parkway LC 340, Minneapolis, MN 55432 (US).

(81) Designated States (*national*): CA, JP.

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DB, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:
— without international search report and to be republished upon receipt of that report

1 of 1 8:26 x 11.69 in Microsoft Word (Word) Adobe Clipbo... Thu, 5/6/04, 11:06am

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/089904 A2


- (51) International Patent Classification⁷: A61N 114th Avenue Northwest, Coon Rapids, MN 55433 (US).
STROM, James; 3740 McCracken Lane, Arden Hills, MN 55112 (US).
- (21) International Application Number: PCT/US02/08889
- (22) International Filing Date: 20 March 2002 (20.03.2002) (74) Agents: WOLDE-MICHAEL, Girma, et al.; Medtronic, Inc., 710 Medtronic Parkway LC 340, Minneapolis, MN 55432 (US).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/850,331 7 May 2001 (07.05.2001) US
- (71) Applicant: MEDTRONIC, INC. [US/US]; 710 Medtronic Parkway LC340, Minneapolis, MN 55432 (US).
- (72) Inventors: FARLEY, Mary, A; 3835 Susan Lane, Minnetonka, MN 55305 (US). JOHNSTONE, George; 6442 Noble Avenue, North, Brooklyn Center, MN 55429 (US). HOCH, Ronald, F; 3426 South Coon Creek Drive, Brooklyn Center, MN 55429 (US). LESSAR, Joseph, F; 3742 (81) Designated States (*national*): CA, JP.
- (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBCUTANEOUS SENSING FEEDTHROUGH/ELECTRODE ASSEMBLY



WO 02/089904 A2

(57) Abstract: Structures and methods relating to electrodes for incorporation into a feedthrough with a profile adapted for subcutaneous sensing of physiologic and cardiac signals. Electrode assemblies are adapted for integration with feedthrough to enable maximal electrode spacing, minimal myopotential electrical noise and provide reliable insulation from the IMD housing. Various structures and manufacturing processes are implemented to provide a large sensing surface with a low profile. The subcutaneous sensing electrode assembly provides a leadless sensing system and further enhances installation and follow-up procedures.

IMPLANTABLE MEDICAL DEVICE WITH DUAL CELL POWER SOURCE

5 The present invention relates to a power source for an implantable medical device. More particularly, it relates to a dual cell power source for optimizing implantable medical device performance.

A variety of different implantable medical devices (IMD) are available for therapeutic stimulation of the heart and are well known in the art. For example, 10 implantable cardioverter-defibrillators (ICDs) are used to treat patients suffering from ventricular fibrillation, a chaotic heart rhythm that can quickly result in death if not corrected. In operation, the ICD continuously monitors the electrical activity of a patient's heart, detects ventricular fibrillation, and in response to that detection, delivers appropriate shocks to restore normal heart rhythm. Similarly, an automatic implantable defibrillator (AID) is available for therapeutic stimulation of the heart. In operation, an AID device 15 detects ventricular fibrillation and delivers a non-synchronous high-voltage pulse to the heart through widely spaced electrodes located outside of the heart, thus mimicking transthoracic defibrillation. Yet another example of a prior art cardioverter includes the pacemaker/cardioverter/defibrillator (PCD) disclosed, for example, in U.S. Patent No. 20 4,375,817 to Engle, et al. This device detects the onset of tachyarrhythmia and includes means to monitor or detect progression of the tachyarrhythmia so that progressively greater energy levels may be applied to the heart to interrupt a ventricular tachycardia or fibrillation. Numerous other, similar implantable medical devices, for example a programmable pacemaker, are further available.

25 Regardless of the exact construction and use, each of the above-described IMDs are generally comprised of three primary components: a low-power control circuit, a high-power output circuit, and a power source. The control circuit monitors and determines various operating characteristics, such as, for example, rate, synchronization, pulse width and output voltage of heart stimulating pulses, as well as diagnostic functions 30 such as monitoring the heart. Conversely, the high-power output circuit generates electrical stimulating pulses to be applied to the heart via one or more leads in response to signals from the control circuit.

The power source "powers" both the low-power control circuit and the high-power output circuit. As a point of reference, the power source is typically required to provide 10-20 microamps to the control circuit and a high power pulse to the output circuit. Depending upon the particular IMD application, the high-power output circuit may require 5 a stimulation energy of as little as 0.1 Joules for pacemakers to as much as 40 Joules for implantable defibrillators. In addition to providing a sufficient stimulation energy, the power source must possess a low self-discharge to have a useful life of many years, must be highly reliable, and must be able to supply energy from a minimum packaged volume.

Suitable power sources or batteries for IMD's are virtually always electrochemical 10 in nature, commonly referred to as an electrochemical cell. Acceptable electrochemical cells for IMDs typically include a case surrounding an anode, a separator, a cathode and an electrolyte. The anode material is typically a lithium metal or, for rechargeable cells, a lithium ion containing body. Lithium batteries are generally regarded as acceptable power sources due in part to their high energy density and low self-discharge characteristics 15 relative to other types of batteries. The cathode material is typically metal-based, such as silver vanadium oxide (SVO), manganese dioxide, etc.

In some cases, the power requirements of the output circuit are higher than the battery can deliver. Thus, it is common in the prior art to accumulate and store the 20 stimulating pulse energy in an output energy storage device at some point prior to the delivery of a stimulating pulse, such as with an output capacitor. When the control circuit indicates to the output circuit that a stimulating pulse is to be delivered, the output circuitry causes the energy stored in the output capacitor to be applied to the cardiac tissue via the implanted leads. Prior to delivery of a subsequent stimulating pulse, the output capacitor must be recharged. The time required for the power source to recharge the 25 output capacitor is referred to as "charge time".

Regardless of whether an output capacitor(s) is employed, one perceived drawback of prior therapeutic pulsing IMDs is that they often have to be replaced before their battery depletion levels have reached a maximum. When an IMD's output capacitor is being 30 recharged, there is a drop in battery voltage due to the charging current flowing through an inherent battery impedance. Although this voltage drop may not be significant when the battery is new or fresh, it may increase substantially as the battery ages or is approaching depletion, such that during a capacitor recharging operation, the voltage supply to the

control circuit may drop below a minimum allowable level. This temporary drop can cause the control circuit to malfunction. The IMD must be removed and replaced before any such malfunctions occur, even though the battery may still have sufficient capacity to stimulate the heart. Simply stated, the rate capability of currently available lithium-based cells is highly dependent upon time or depth-of-discharge as the cell develops high internal resistance over time and/or with repeated use. For IMD applications, this time or depth-of-discharge dependence limits the battery's useful life.

One solution to the above-described issue is to provide two batteries, one for charging the output circuit or capacitor and a separate battery for powering the control circuit. Unfortunately, the relative amounts of energy required of the device for the control and charging/output circuitry will vary from patient to patient. The capacity of the battery to power the control circuit can only be optimized with regard to one patient profile. For all other patients, one battery will deplete before the other, leaving wasted energy in the device. An example of such a system is disclosed in U.S. Patent No. 15 5,614,331 to Takeuchi et al.

An additional, related concern associated with IMD power sources relates to overall size constraints. In particular, in order to provide an appropriate power level for a relatively long time period (on the order of 4-7 years), the power source associated with the high-power output circuitry must have a certain electrode surface area to achieve the high-rate capability. Due to safety and fabrication constraints, the requisite electrode surface area can only be achieved with an increased cell volume. The resulting cell will satisfy output circuitry power requirements, but unfortunately will be volumetrically inefficient. Even further, recent IMD designs require the power source to assume a shape other than rectangular, such as a "D" or half "D" contours, further contributing to volumetric inefficiencies. In general terms, then, currently available electrochemical cell designs, especially Li/SVO constructions, will satisfy, at least initially, power requirements for the output circuitry. The inherent volumetric inefficiencies of these cells, however, dictates an end-of-life point at which less than the cell's useful capacity has been used. Once again, currently available cells exhibit an output circuitry charge time that is highly dependent upon time of use or depth-of-discharge. Over time, the cell's impedance increases, thereby increasing the resulting charge time. Virtually all IMDs have a maximum allowable charge time for the output circuitry. Once the cell's charge time

5 exceeds the maximum allowable charge time, the IMD must be replaced. The volumetrically inefficient cell will quickly reach this maximum charge time, even though a large portion of the cell's capacity remains unused (on the order of 40% of the useful capacity). Thus, regardless of whether the power source incorporates one or two cells, the resulting configuration is highly inefficient in terms of the high-rate battery's useful capacity.

10

Manufacturers continue to improve upon IMD construction and size characteristics. To this end, currently available power source designs are less than optimal. Therefore, a need exists for an IMD power source having superior space-volumetric efficiencies and a higher energy density, without a proportional increase in charge time.

15

Summary of the Invention

20

One aspect of the present invention provides an implantable medical device including a hermetic enclosure, a low-power control circuit, a high-power output circuit, and a power source and associated circuitry. The low-power control circuitry is located within the enclosure. The high-power output circuit is similarly located within the enclosure and is provided to deliver an electrical pulse therapy. Finally, the power source and associated circuitry is located within the enclosure for powering both the low-power control circuit and the high-power output circuit. The power source and associated circuitry includes a first, high-rate cell, a second, lower-rate cell and a switching circuit. The second, lower-rate cell has a rate capability less than that of the first, high-rate cell, such as with a medium-rate cell or a low-rate cell. The first, high-rate cell and the second cell are electrically connected in parallel to the low-power control circuit and the high-power output circuit. Finally, the switching circuit is electrically connected between the first, high-rate cell and the low-power control circuit. The switching circuit selectively uncouples the first, high-rate cell from the low-power control circuit upon activation of the high-power output circuit. During use, both the first, high-rate cell and the second cell operate in parallel during normal device operation. During operation of the high-power output circuitry, such as a transient high power pulse, the switching circuit disconnects the first, high-rate cell from the low-power control circuit. Requisite power is continuously supplied to the low-power control circuit during the high power pulse by the lower-rate cell.

25

30

Another aspect of the present invention relates to an implantable medical device including a hermetic enclosure, a low-power control circuit, a high-power output circuit and a power source. The low-power control circuit and the high-power output circuit are located within the enclosure. The high-power output circuit is provided to deliver an electrical pulse therapy. The power source is similarly located within the enclosure and is provided to power the low-power control circuit and the high-power output circuit. With this in mind, the power source includes a case, first anode and cathode bodies, second anode and cathode bodies and an electrolyte. The first anode and cathode bodies, as well as the second anode and cathode bodies, are disposed within the case. The electrolyte is similarly contained within the case. With this configuration, the first anode and cathode bodies combine to effectively form a first cell, and the second anode and cathode bodies combine to effectively form a second cell, with the first and second cells being activated by a common electrolyte. Finally, the first and second cells are electrically connected in parallel to the low-power control circuit and the high-power output circuit. In one preferred embodiment, the first cell is a high-rate cell, whereas the second cell is a lower-rate cell. Regardless, during use, the first and second cells operate in parallel to power the low-power control circuit and the high-power output circuit. During operation of the high-power output circuit, the first cell provides requisite power to the high-power output circuit, whereas the second cell powers the low-power control circuit. In one preferred embodiment, the second cell acts to at least partially re-charge the first cell.

Yet another aspect of the present invention relates to an implantable medical device including a hermetic enclosure, a low-power control circuit, a high-power output circuit, and a power source. The low-power control circuit and the high-power output circuit are located within the enclosure, with the high-power output circuit configured to deliver an electrical pulse therapy. The power source is similarly located within the enclosure and powers the low-power control circuit and the high-power output circuit. The power source includes a first, high-rate cell and a second, lower-rate cell having a rate capability less than a rate capability of the first, high-rate cell. More particularly, the first, high-rate cell includes an anode, a cathode and an electrolyte. The first, high-rate cell is characterized by a rate capability exhibiting minimal dependence on time up to a preselected, voltage-based elective replacement indicator (ERI) at which at least 50% of the cathode is consumed. In one preferred embodiment, the high-rate cell is a lithium-

5 limited cell characterized by a rate capability exhibiting minimal dependence upon depth-of-discharge up to the ERI. During use, the high-rate cell powers the high power control circuit. Because high-rate cell performance is essentially independent of time, a substantially uniform charge time for the high-power output circuit is achieved, while
the lower-rate cell insures consistent low-power control circuit operation.

Brief Description of the Drawings

10 FIG. 1 is a simplified schematic view of one embodiment of an implantable medical device (IMD) incorporating a power source in accordance with the present invention;

FIG. 2 is a simplified schematic circuit diagram of a power source in accordance with the present invention for use with the IMD of FIG. 1;

FIG. 3 is a simplified schematic diagram of a first embodiment power source in accordance with the present invention;

15 FIG. 4 is a simplified schematic diagram of a second embodiment power source in accordance with the present invention;

FIG. 5A is a cross-sectional view of a third alternative embodiment power source in accordance with the present invention;

FIG. 5B is a cross-sectional view of a variation of the embodiment of FIG. 5A;

20 FIG. 5C is a perspective view of the power source of FIG. 5A including an internal, parallel connection;

FIG. 6 is a top view of a fourth embodiment power source in accordance with the present invention;

25 FIG. 7 is a cross-sectional view of an IMD incorporating a fifth embodiment power source;

FIG. 8 is a simplified schematic diagram of a sixth embodiment power source;

FIG. 9 is a graph showing a discharge curve for a conventionally balanced battery; and

30 FIG. 10 is a graph showing a discharge curve for an anode limited battery for use with the power source of FIG. 8.

Detailed Description of the Preferred Embodiments

FIG. 1 is a simplified schematic view of one embodiment of an implantable medical device ("IMD") 20 in accordance with the present invention and its relationship to a human heart 22. The IMD 20 is shown in FIG. 1 as preferably being a pacemaker/cardioverter/defibrillator (PCD) and includes a case or hermetic enclosure 23 and associated electrical leads 24, 26 and 28. As described in greater detail below, the enclosure case 23 contains various circuits (not shown) and a power source (not shown). The leads 24, 26 and 28 are coupled to the IMD 20 by means of a multi-port connector block 30, which contains separate ports for each of the three leads illustrated 24, 26, and 28.

The lead 24 is coupled to a subcutaneous electrode 40, which is intended to be mounted subcutaneously in the region of the left chest. Alternatively, an active "can" may be employed.

The lead 26 is a coronary sinus lead employing an elongated coil electrode that is located in the coronary sinus and great vein region of the heart 22. The location of the electrode is illustrated in broken line format at 42, and extends around the heart 22 from a point within the opening of the coronary sinus to a point in the vicinity of the left atrial appendage.

The lead 28 is provided with an elongated electrode coil 38 which is located in the right ventricle of the heart 22. The lead 28 also includes a helical stimulation electrode 44 which takes the form of an advanceable helical coil which is screwed into the myocardial tissue of the right ventricle. The lead 28 may also include one or more additional electrodes for near and far field electrogram sensing.

In the system illustrated, cardiac pacing pulses are delivered between the helical electrode 44 and the elongated electrode 38. The electrodes 38 and 44 are also employed to sense electrical signals indicative of ventricular contractions. As illustrated, it is anticipated that the right ventricular electrode 38 will serve as the common electrode during sequential and simultaneous pulse multiple electrode defibrillation regimens. For example, during a simultaneous pulse defibrillation regimen, pulses would simultaneously be delivered between the electrode 38 and the electrode 40, and between the electrode 38 and the electrode 42. During sequential pulse defibrillation, it is envisioned that pulses would be delivered sequentially between the subcutaneous electrode 40 and the electrode

38, and between the coronary sinus electrode 42 and the right ventricular electrode 38. Single pulse, two electrode defibrillation pulse regimens may also be provided, typically between the electrode 38 and the coronary sinus electrode 42. Alternatively, single pulses may be delivered between the electrodes 38 and 40. The particular interconnection of the 5 electrodes to the IMD 20 will depend somewhat on the specific single electrode pair defibrillation pulse regimen is believed more likely to be employed.

The IMD 20 may assume a wide variety of forms other than the preferred PCD configuration depicted in FIG. 1. For example, the IMD 20 may be an implantable cardiac defibrillator (ICD) as is known in the art. Alternatively, or in addition, the IMD 10 may 10 be an implantable cardiac pacemaker, an implantable neurostimulator, an implantable drug pump, a cardiomystimulator, etc., all of which are known in the art.

Regardless of the exact configuration and operation of the IMD 20, the IMD 20 includes several basic components, illustrated in block form in FIG. 2. The IMD 20 includes a high-power output circuit 50, a low-power control circuit 52, a power source 54 15 (shown with dashed lines) and circuitry 56. As described in greater detail below, the power source 54 is preferably a dual-cell configuration, and can assume a wide variety of forms. Similarly, the circuitry 56 can assume a variety of configurations, and electrically connects the power source 54 to the high power circuit 50 and the low-power circuit 52.

The high-power output circuit 50 and the low-power control circuit 52 are typically 20 provided as part of an electronics module associated with the IMD 20. In general terms, the high-power output circuit 50 is configured to deliver an electrical pulse therapy, such as a defibrillation or a cardioversion/defibrillation pulse. In sum, the high-power output circuit 50 is responsible for applying stimulating pulse energy between the various electrodes 38-44 (FIG. 1) of the IMD 20. As is known in the art, the high-power output 25 circuit 50 may be associated with a capacitor bank (not shown) for generating an appropriate output energy, for example in the range of 0.1-40 Joules.

The low-power control circuit 52 is similarly well known in the art. In general terms, the low-power control circuit 52 monitors heart activity and signals activation of the high-power output circuit 50 for delivery of an appropriate stimulation therapy. 30 Further, as known in the art, the low-power control circuit 52 may generate a preferred series of pulses from the high-power output circuit 50 as part of an overall therapy.

The power source 54 and associated circuitry 56 can assume a wide variety of configurations, as described in the various embodiments below. Preferably, however, the power source 54 includes a first, high-rate cell 60 and a second, lower-rate cell 62, such as a medium- or low-rate cell. Notably the first and second cells 60, 62 can be formed separate from one another or contained within a singular enclosure. Depending upon the particular application, the high-rate cell 60 is configured to provide a stimulation energy of as little as 0.1 Joules for pacemakers to as much as 40 Joules for implantable defibrillators.

5 As described below with reference to specific embodiments, the high-rate cell 60 can assume a wide variety of forms as is known in the art. Preferably, the high-rate cell 60 includes an anode, a cathode and an electrolyte. The anode is preferably formed to include lithium, either in metallic form or ion form for re-chargeable applications. With this in mind, the high-rate cell 60 is most preferably a spirally-wound battery of the type disclosed, for example, in U.S. Patent No. 5,439,760 to Howard et al. for "High Reliability Electrochemical Cell and Electrode Assembly Therefor" and U.S. Patent No. 5,434,017 to

10 Berkowitz et al. for "High Reliability Electrochemical Cell and Assembly Therefor," the disclosures of which are hereby incorporated by reference. The high-rate cell 60 may less preferably be a battery having a spirally-wound, stacked plate or serpentine electrodes of the type disclosed, for example, in U.S. Patent Nos. 5,312,458 and 5,250,373 to Muffuletto et al. for "Internal Electrode and Assembly Method for Electrochemical Cells,"

15 U.S. Patent No. 5,549,717 to Takeuchi et al. for "Method of Making Prismatic Cell;" U.S. Patent No. 4,964,877 to Kiester et al. for "Non-aqueous Lithium Battery;" U.S. Patent No. 5,14,737 to Post et al. for "Electrochemical Cell With Improved Efficiency Serpentine Electrode;" and U.S. Patent No. 5,468,569 to Pyszczek et al. for "Use of Standard Uniform Electrode Components in Cells of Either High or Low Surface Area Design," the

20 disclosures of which are herein incorporated by reference. Alternatively, the high-rate cell 60 can include a single cathode electrode.

25

Materials for the cathode of the high-rate cell 60 are most preferably solid and comprise as active components thereof metal oxides such as vanadium oxide, silver vanadium oxide (SVO) or manganese dioxide, as is known in the art. Alternatively, the cathode for the high-rate cell 60 may also comprise carbon monoflouride and hybrids thereof or any other active electrolytic components and combination. Where SVO is employed for the cathode, the SVO is most preferably of the type known as "combination

silver vanadium oxide" (or "CSVO") as disclosed in U.S. Patent Nos. 5,221,453; 5,439,760; and 5,306,581 to Crespi et al, although other types of SVO may be employed.

It is to be understood that electrochemical systems other than those set forth explicitly above may also be utilized for the high-rate cell 60, including, but not limited to, 5 anode/cathode systems such as lithium/silver oxide; lithium/manganese oxide; lithium/V₂O₅; lithium/copper silver vanadium oxide; lithium/copper oxide; lithium/lead oxide; lithium/carbon monoflouride; lithium/chromium oxide; lithium/bismuth-containing oxide; lithium/copper sulfate; mixtures of various cathode materials listed above such as a mixture of silver vanadium oxide and carbon monoflouride; and lithium ion re-chargeable 10 batteries, to name but a few.

In general terms, the second, lower-rate cell 62 has a rate capability that is less than that of the high-rate cell 60, and is sufficient to power the low-power control circuit 52. For example, in one preferred embodiment, the second, lower-rate cell 62 is a medium 15 rate, SVO cell, more preferably SVO/CF_x cell. Alternatively, the second, lower-rate cell 62 can be a low-rate, lithium/iodine pacemaker battery having a current drain in the range of 10-30 microamps. As known in the art, acceptable constructions of the second, lower-rate cell 62 include, for example, a single cathode electrode design described in U.S. Patent No. 5,716,729 to Sunderland et al. for "Electrochemical Cell," the disclosure of which is incorporated by reference. As used throughout the specification, reference to a 20 "lower-rate cell" includes both a low-rate cell and a medium-rate cell. Regardless of the exact construction, the high rate cell 60 and the lower-rate cell 62 preferably have similar beginning of life (BOL) voltages (e.g., less than 100 mV). Further, it is preferred that the cells 60, 62 have similar depletion voltages so that the capacity of each of the cells 60, 62 is efficiently used when the first of the cells 60 or 62 reaches depletion.

With the above-described parameters of the high-rate cell 60 and the second, lower-rate cell 62 in mind, one preferred combination A of a power source 54A and circuitry 56A is depicted schematically in FIG. 3. The power source 54A includes a first, high-rate cell 60A and a second, lower-rate cell 62A as described above. In addition, circuitry 56A electrically connects the high-rate cell 60A and the lower-rate cell 62A in parallel to the high-power output circuit 50 and the low-power control circuit 52. In particular, the circuitry 56A includes a switch 70 configured to selectively uncouple the 30 high-rate cell 60 from the low-power control circuit 52. In this regard, the circuitry 56A

can include additional components/connections (not shown) for activating and deactivating the switch 70 in response to operational conditions described below.

The power source/circuitry configuration A provides a distinct advantage over prior art, single-cell designs. For example, during operation of the IMD 20 (FIG. 1), the power source 54A is, from time-to-time, required to deliver a high-current pulse or charge to the high-power output circuit 50 while maintaining a voltage high enough to continuously power to the low-power control circuit 52. If the supply voltage drops below a certain value, the IMD 20 will cease operation. The power source/circuitry configuration A places the high-rate cell 60A and the lower-rate cell 62A in parallel to power the low-power control circuit 52 during periods when the high-power output circuit 50 is not activated. During a transient high power pulse, such as a defibrillation pulse, the switch 70 is operated uncouple the high-rate cell 60A from the low-power control circuit 52. The lower-rate cell 62A remains electrically connected to the low-power control circuit 52. Thus, the lower-rate cell 62A continuously powers the low-power control circuit 52, regardless of any voltage drop experienced by the high-rate cell 60A. With the parallel configuration of the circuitry 56A, the high-rate cell 60A and the lower-rate cell 62A can be operated in combination for approximately the entire useful life of the respective cells 60A, 62A. Further, where desired, the cells 60A and/or 62A can be sized and shaped to satisfy certain volumetric or shape constraints presented by the IMD 20 (FIG. 1).

An alternative embodiment power source/circuitry configuration B is depicted schematically in FIG. 4. The power source/circuitry configuration B includes a power source 54B and circuitry 56B. The power source 54B includes a first, high-rate cell 60B and a second, lower-rate cell 62B. The circuitry 56B connects the high-rate cell 60B and the lower-rate cell 62B in parallel with the high-power output circuit 50 and the low-power control circuit 52, and includes a switch 80. The switch 80 is configured to selectively uncouple the high-rate cell 60B from the low-power control circuit 52, such that the circuitry 56B can include additional components/connections (not shown) for activating and deactivating the switch 80 in response to operational conditions described below.

The power source 54B is preferably a reservoir battery whereby both the high-rate cell 60B and the lower-rate cell 62B are maintained within a single case, shown generally

at 82. In this regard, the high-rate cell 60B includes an anode/cathode combination that is electrochemically correlated (preferably identical) with an anode/cathode construction of the lower-rate cell 62B such that a common electrolyte 84 activates both cells 60B, 62B. For example, the high-rate cell 60B can be a high-rate Li/SVO, whereas the lower-rate cell 5
62B is a high-volumetric efficiency cell such as Li/SVO or a Li/MnO₂ cell with a pellet design. Alternatively, other constructions for the cells 60B, 62B, as previously described, are equally acceptable.

Connecting the cells 60B, 62B in parallel, via the circuitry 56B, to the high-power output circuit 50 and the low-power control circuit 52 allows for both cells 60B, 62B to power the low-power control circuit 52, thereby extending the useful life of the power source 54B. Further, as with the power source/circuitry configuration A (FIG. 3) 10 previously described, the switch 80 ensures low-power control circuit 52 operation during transient high power pulses by the high-power output circuit 50. For example, when the high power output circuit 50 is prompted to deliver a high power pulse or charge, the circuitry 56B activates the switch 80 to uncouple the high-rate cell 60B from the low-power control circuit 52. The lower-rate cell 62B remains electrically connected, 15 providing continuous, uninterrupted power to the low-power control circuit 52.

In addition, the lower-rate cell 62B can serve to recharge the high-rate cell 60B. More particularly, after the high-rate cell 60B is pulsed, the potential of the high-rate cell 20 60B will be lower than that of the lower-rate cell 62B. When the lower-rate cell 62B is re-connected to the high-rate cell 60B (via the switch 80), the lower-rate cell 62B will be discharged and the high-rate cell 60B correspondingly charged until they reach equal potentials. Electrons move from the anode of the lower-rate cell 62B to the anode of the high-rate cell 60B, and from the cathode of the high-rate cell 60B to the cathode of the 25 lower-rate cell 62B. In one preferred embodiment, for recharging to occur, the high-rate cell 60B must possess at least some degree of rechargeability. That is to say, the high-rate cell 60B may not be rechargeable per the above description if discharged to a high degree. It has surprisingly been found that configuring the high-rate cell 60B to exhibit a "micro-rechargeability" characteristic allows the small amount of capacity removed during 30 operation of the high-power output circuit 50 (e.g., a therapy) to be replaced. It has further surprisingly been found that a high-rate cell 60B including an SVO cathode exhibits this desired micro-rechargeability characteristic. Alternatively, other cathode materials may

also be acceptable. Notably, this same recharging mechanism applies to the configuration A (FIG. 3) previously described.

As an additional advantage, the high-rate cell 60B can be sized (e.g., cell volume) to satisfy the requirements of the high-power output circuit 50, without specific concern for powering the low-power control circuit 52. As previously described, with prior art, single cell designs, cell volume is highly inefficient. The power source 54B overcomes this problem by minimizing the size of the high-rate cell 60B, and utilizing a more conveniently sized lower-rate cell 62B. In other words, the high-rate cell 60B can be a relatively simple shape that is conducive to coiled, serpentine, or other high-electrode area construction (but possibly with a lower volumetric energy density), whereas the lower-rate cell 62B can be of a shape that conforms and efficiently utilizes a desired volumetric shape of the IMD 20 (i.e., such as a "D"-shaped pellet or bobbin cell with a relatively high volumetric energy density). The resulting power source 54B, by virtue of its unique, complex shape, utilizes the volume available in the IMD 20 and thus contributes to the IMD 20 having an optimal volume.

Yet another alternative embodiment power source/circuitry configuration C is depicted in cross-section in FIG. 5A. More particularly, FIG. 5A shows a power source 54C including a high-rate cell 60C, and a reservoir pellet 90 and a lithium body 92 that serve as a lower-rate cell 62C. The high-rate cell 60C, the pellet 90, and the lithium body 92 are disposed within a case 94 further containing an electrolyte 96. Although not shown in FIG. 5A, the high-rate cell 60C and the lower-rate cell 62C (comprised of the reservoir cathode pellet 90 and the lithium body 92) are connected in parallel to the high-power output circuit 50 (FIG. 2) and the low-power control circuit 52 (FIG. 2) by circuitry (not shown) that may or may not include a switch. Further, the lithium body 92 is and has approximately the same length and width as the cathode reservoir pellet 90.

The high-rate cell 60C can assume a number of constructions, but preferably includes a coiled anode 98 and cathode 100. For example, the anode 98 is preferably a lithium material, whereas the cathode 100 is an appropriate metal-containing material (e.g., a metal oxide or metal sulfide), preferably SVO. Regardless, the anode 98 and the cathode 100 are preferably wound about the reservoir pellet 90. Alternatively, the reservoir pellet 90 and the lithium body 92 can be positioned outside of the winding of the high-rate cell 60C, as shown, for example, by the alternative embodiment of FIG. 5B.

Returning to FIG. 5A, the reservoir pellet 90 is of the same composition as the cathode 100. For example, in a preferred embodiment, the reservoir pellet 90 is a dense SVO or MnO₂ cathode pellet. Similarly, the lithium body 92 is of the same composition as the anode 98, and serves to balance the capability of the reservoir pellet 90. In this regard, the lithium body 92 need not be a separate element, but instead an inner most turn 102 of the anode 98 (i.e., surrounding the reservoir pellet 90) can be thickened (i.e., provided with additional lithium material).

The power source/circuitry configuration C provides the power source 54C with a higher energy density than a conventional parallel plate or coil configuration by utilizing the reservoir pellet 90 to charge the high-rate cell 60C without the difficulties of fabricating, coiling, or folding multiple thick electrodes.

During use, the high-rate cell 60C and the reservoir pellet 90 operate in parallel to power the low power control circuit 52 (FIG. 2). During a transient high-pulse operation, the high-rate cell 60C and the reservoir pellet 90 operate to power the high-power output circuit 50 (FIG. 2). Most of the power is delivered by the high-rate cell 60C due to its low internal resistance as compared to the lower-rate cell 62C (again, defined by the reservoir cathode pellet 90 and the lithium body 92). Following transient high-pulse operation, the lower-rate cell 62C preferably acts to recharge the high-rate cell 60C as previously described with respect to the power source 54B (FIG. 4). In particular, the reservoir pellet 90 serves as an auxiliary cathode, accepting electrons and lithium ions from the cathode 100 following the transient high-pulse operation. For example, where the reservoir pellet 90 is comprised of a material that is chemically compatible with the composition of the cathode 100 (e.g., SVO or MnO₂), as the high-rate cell 60C is discharged, the cathode 100 is charged or oxidized by the flow of electrons and lithium ions between the cathode 100 and the reservoir pellet 90. The resulting power source 54C has a higher average voltage, a higher volumetric energy density and an improved end of life voltage signal than a similar cell without the reservoir pellet 90. Further, the lithium body 92 balances the capacity of the reservoir pellet 90, thereby promoting recharging of the high-rate cell 60C following a transient high power pulse.

In one more preferred embodiment of the power source 54C, the high-rate cell 60C and the lower-rate cell 62C (or the reservoir pellet 90) are connected in parallel, internal to the power source 54C itself. For example, FIG. 5C illustrates one interconnection

technique associated with the configuration C of FIG. 5A. As a point of reference, a portion of the case 94 has been removed to better illustrate component interconnection. With this in mind, the power source 54C further includes a first conductive tab 102, a second conductive tab 104, and a connector 106. The first tab 102 is connected to and extends from the cathode 100 associated with the high-rate cell 60C. Conversely, the second tab 104 is connected to and extends from the reservoir (or cathode) pellet 90 forming the lower-rate cell 62C. Finally, the connector 106 interconnects the tabs 102, 104, and terminates in a feed through pin 108 otherwise extending outwardly from the battery case 94.

By internally connecting the cells 60C and 62C in parallel, only a single one of the feedthroughs 108 is required, thereby reducing the costs and complexities of other dual battery designs in which two or more feedthroughs are required. It will be understood that the construction of FIG. 5C necessitates that the cells 60C, 62C are not independently dischargeable, and a switch, such as the switch 80 of FIG. 4 is not available. However, the design promotes shape flexibility and volumetric efficiency. For example, one particular manufacturing concern associated with high-energy IMD power supplies is the requirement, due to known safety concerns, of a wound cell utilizing thick cathode. Where a wound design is employed, the thick cathode material tends to crack in the corners and transmits stress through other components (such as a separator plate and/or lithium anodes). This may, in turn, lead to internal shorts. With the configuration of FIG. 5C, however, a substantial fraction of the energy supply is stored in the reservoir pellet 90 (or lower rate cell 62C), and the adjacent lithium body 92. The pellet 90 is not wound, and thus can be relatively thick without presenting the stress concerns associated with a wound cathode material. Because a substantial fraction of the energy is stored in the pellet 90, the cathode 100 material associated with the high-rate cell 60C can now be relatively thin, and thus more readily wound without experiencing stress-related defects. Further, by forming the reservoir pellet 90 to be relatively thick, a radius of the inner most winding associated with the high rate cell 60C is increased or greater than that found with conventional wound cells, again reducing winding-caused stress.

Yet another alternative power source/circuitry configuration D having enhanced volumetric efficiency is depicted schematically in FIG. 6. The configuration D includes a power source 54D and circuitry 56D. The power source 54D includes a case 110

5 maintaining a high-rate cell 60D, a lower-rate cell 62D, and an electrolyte (not shown). The circuitry 56D connects the cells 60D, 62D in parallel with the high-power output circuit 50 (FIG. 2) and the low-power control circuit 52 (FIG. 2). Although illustrated schematically in FIG. 6, the high-rate cell 60D can assume any of the forms previously
10 described and is preferably of a simple shape such that is conducive to assuming a coiled, serpentine, or other high-surface area electrode configuration. Conversely, the lower-rate cell 62D is a relatively low-surface area auxiliary electrode assuming an irregular shape, such as a D-shape, otherwise conforming and efficiently utilizing an available volume of the case 110. Once again, the lower-rate cell 62D can be comprised of any of the material(s) previously described, and can be a medium- or low-rate cell. Regardless, the resulting power source 54D, by virtue of its unique, complex shape, utilizes the volume
15 available in the IMD 20 (FIG. 1) and thus contributes to an optimally sized device.

10 In operation, the power source 54D operates similar to previous embodiments, with the high-rate cell 60D and the lower-rate cell 62D operating in parallel to power the high-power output circuit 50 (FIG. 2) and the low-power control circuit 52 (FIG. 2). In this regard, the circuitry 56D associated with the power source 54D may include a switch (not shown) that uncouples the high-rate cell 60D from the low-power control circuit 52 during transient high power pulses. Operation of the lower-rate cell 62D in isolation from the high-rate cell 60D will continuously power the low-power control circuit 52 without concern for the voltage drop associated with the high-rate cell 60D. Further, when the power source 54D is subjected to a high-current pulse discharge, the high-rate cell 60D and the lower-rate cell 62D will equilibrate between pulses and thus stay at the same depth
20 of discharge, with most of the capacity of the high-rate cell 60D being discharged at a higher voltage than would be observed without the lower-rate cell 62D connected in parallel.
25

30 Yet another, related alternative power source/circuitry configuration E having enhanced volumetric efficiency is depicted as part of an IMD 112 in FIG. 7. More particularly, the IMD 112 is shown as including a case 114, a circuit 116 (shown generally in FIG. 7), and the power source 54E. The power source 54E includes a high-rate cell 60E and a lower rate 62E. With the embodiment of FIG. 7, the cells 60E, 62E are separately formed (i.e., separate enclosures) and are connected in parallel via circuitry 56E. Notably,

the circuitry 56E does not include a switch, and the cells 60E, 62E are not independently dischargeable.

Though illustrated schematically in FIG. 7, the high-rate rate cell 60E can assume any of the forms previously described and is preferably of a simple shape, conducive to assuming a coiled, serpentine, or other high-surface area electrode configuration. Conversely, the lower-rate cell 62E is a relatively low-surface area auxiliary electrode shaped to efficiently utilize an available volume of the case 114. In one preferred embodiment, the high-rate cell 60E is a thin film battery known in the art. In this regard, one preferred method of manufacturing a thin electrode is to prepare a slurry of electrode material in an appropriate solvent. This slurry is then applied to a thin foil substrate as the current collector. To this end, the most common method is to use a "knife over roller" approach, whereby the slurry is applied to a moving web (e.g., the metal foil) using a knife edge to control thickness (i.e., a Doctor blade). The solvent is then evaporated leaving a thin film of cathode material. Alternatively, other known thin electrode manufacturing techniques are equally acceptable.

By forming the high rate cell 60E as a thin film battery, the power source 54E is characterized by an improved volumetric efficiency. Further, especially where the IMD 112 is an ICD, the power source 54E presents improved scaleability. As a point of reference, ICD batteries are typically built with maximum safe power capability (i.e., maximum safe electrode surface area). Thus, changing the size of a "standard" ICD battery in one dimension while maintaining a specific surface area typically imposes more geometric constraints than can be satisfied. As a result, for differently sized ICD applications, the "standard" ICD battery must often be changed in two dimensions, and therefore is not scaleable. The dual cell design of FIG. 7 overcomes this problem. In particular, by forming the high-rate cell 60E as a thin electrode allows the high-rate cell 60E to be located underneath the circuit 116. Conversely, the lower rate cell (preferably a medium-rate cell) 62E is constructed to have the same thickness as the internal dimensions of the case 114 (i.e., the same thickness as the circuits 116 and the high-rate cell 60E). As shown in FIG. 7, then, the lower rate cell 62E is positioned adjacent the circuit 116/high-rate cell 60E stack. The high-energy capacitors (not shown) of the ICD 112 are located on the other side of the medium-rate cell 62E and match the medium rate cell 62E in thickness. For a differently sized ICD, the lower rate cells 62E can be scaled in one

dimension to provide the energy needs for a particular application. However, the circuit 116, the high-rate cell 60E, the capacitors, and any device connector blocks (not shown) are all fixed components that do not vary. Thus, the configuration of FIG. 7 meets desired scaleability criteria.

5 Another alternative embodiment power source/circuitry configuration F is depicted schematically in FIG. 8. The configuration F includes a power source 54F and associated circuitry 56F. Once again, the power source 54F includes a first, high-rate cell 60F and a second, lower-rate cell 62F. The circuitry 56F connects the high-rate cell 60F and the lower-rate cell 62F to the high-power output circuit 50 and the low-power control circuit 10 52. Unlike previous embodiments, the circuitry 56F need not necessarily connect the cells 60F, 62F in parallel. Further, while the lower-rate cell 62F is highly similar to previously described embodiments, the high-rate cell 60F is preferably an anode limited cell as described below.

15 In particular, for the configuration F, the high-rate cell 60F includes a solid cathode, liquid organic electrolyte and a lithium anode for delivering high current pulses. The cell 60F further includes a casing (not shown) containing the cell components and the cathode structure therein is wound in a plurality of turns, with the lithium anode interposed between the turns of the cathode winding. The casing also contains a non-aqueous liquid 20 organic electrolyte preferably comprising a combination of lithium salt and an organic solvent operatively contacting the anode and the cathode. An electrical connection is provided to the anode and an electrical connection is provided to the cathode. The cathode includes an active material such as SVO or MnO₂.

With the above-construction, the high-rate cell 60F is a volumetrically constrained system. The amounts of each component that goes into the cell 60F (cathode, anode, 25 separator, current collectors, electrolytes, etc.) cannot exceed the available volume of the battery case. In addition, the appropriate amount of some components depends upon the amount of other components that are used. These components must be "balanced" to provide discharge to the extent desired.

For example, in a cathode limited Li/SVO battery (all conventionally balanced 30 Li/SVO batteries known to date are of this type) such as is used in a defibrillator application, the capacity (Q_+) of the cathode must not exceed the capacity (Q_-) of the anode. The volume occupied by the other battery components also depends on the cathode

capacity (Q_+) as reflected by the amount of cathode material in the battery. All of the battery components must be adjusted for a given battery volume.

Conventionally balanced lithium anode cells used with ICDs are balanced with sufficient lithium and electrolyte to discharge the cathode to completion. However, 5 conventionally balanced cells have impedances that increase with time and depth-of-discharge. The power capability of these cells is limited by electrode area constraints imposed for safety reasons. Historically, it has been possible to use nearly the total capacity of the battery while maintaining adequate power (i.e., acceptable charge times). However, over time, conventionally balanced high-rate cells exhibit increased charge 10 times due to increased cell impedance. When the cell can no longer satisfy charge time requirements, the ICD (or other IMD) must be replaced. To this end, industry standards have implemented more rigorous charge time requirements. Hence, it has become increasingly difficult to use the entire cell capacity before charge time failure.

One example of the above-described concern experienced by a Li/SVO type cell is 15 illustrated graphically in FIG. 9. In particular, a conventional, Li/SVO high-rate cell design experiences a decrease in voltage over time as shown by curve 120. In addition, due to the increase in internal resistance over time results in an increasing capacitor charge time, as represented by the curve 122. As a point of reference, the curves 120, 122 extend from a beginning of life (BOL) point to an end of life (EOL) point. Just prior to EOL, manufacturers typically delineate a potential loss of function (indicated at "PLF" in FIG. 20 9) for the power source with respect to a particular IMD application. PLF is determined by circuit performance requirements of the IMD. For the example of FIG. 9, according to manufacturer standards, the conventionally balanced cell will experience a potential loss of function (PLF) at approximately 2.20 volts. To ensure that the IMD is explanted and 25 replaced prior to PLF, industry standards require the IMD to provide an elective replacement indicator (ERI) to the user. The ERI is normally designated by the manufacturer with reference to the voltage curve 120 just prior to the PLF. For example, a manufacturer's standards may require that the IMD continue to operate for three months after ERI. With this standard in mind, the manufacturer works backwards from the PLF to 30 select an ERI value that satisfies the so-selected standard. With reference to the example of FIG. 9, a common ERI value is 2.45 volts.

With the above definitions in mind, FIG. 9 illustrates graphically that the charge time curve 122 is dependent upon depth-of-discharge or time, increasing from BOL to both ERI and PLF. Due to this time dependence, and as a point of reference, the charge time for a typical high-rate cell useful with an IMD is approximately 8 seconds at BOL, 14
5 seconds at ERI, and 25 seconds at PLF. As IMD performance requirements continue to evolve, it is highly likely that charge times in excess of 16 seconds may no longer be acceptable. In other words, future industry requirements may require a PLF value of 16 seconds (and thus a correspondingly decreased ERI value). While an IMD incorporating a lithium-based high-rate cell can be programmed to provide an earlier ERI signal (relative
10 to the charge time curve 120), due to the dependence upon depth-of-discharge or time, only a small portion of the battery's capacity will be used at this reduced ERI level. For example, at ERI corresponding with a charge time of 12 seconds, approximately 40% of a conventional cell's capacity has been used. Obviously this low efficiency is highly undesirable.

To overcome the time-dependent characteristics associated with previous lithium-based high-rate cells, the power source 54F (FIG. 8) forms the high-rate cell 60F (FIG. 8) to be anode limited. In particular, the high-rate cell 60F is preferably a lithium limited cell as described, for example, in U.S. Patent No. 5,458,997, the teachings of which are incorporated herein by reference. Generally speaking, available lithium-based high-rate cells, such as Li/SVO, Li/MnO₂, etc., are re-balanced such that the cell contains sufficient lithium and electrolyte to be discharged only to a first voltage plateau (labeled as 124 in FIG. 8). The volume made available by using less lithium and electrolyte allows more room for cathode material, thereby extending the first voltage plateau as shown by the dotted line 126. With this configuration, the lithium anode is depleted prior to cathode
20 depletion, thereby prohibiting the formation of gas. In addition, the lithium limited design generates minimal impedance over a majority of the battery's life. In one preferred embodiment, the lithium limited, high-rate cell 60F is a SVO/CF_x hybrid cathode design,
25 where x is in the range of 0.9-1.1.

As illustrated graphically in FIG. 10, the lithium limited high-rate cell 60F (FIG. 8) exhibits charge time characteristics that have little dependence upon depth-of-discharge or time. As a point of reference, FIG. 10 depicts a voltage curve 130 and a charge time curve 132. As compared to the conventionally balanced cell performance characteristics

illustrated in FIG. 9, the voltage curve 130 of the lithium limited high-rate cell 60F has an extended first voltage plateau 134, and a rapid voltage decrease after the second voltage plateau 136. Importantly, however, prior to a second voltage plateau 136, the charge time curve 132 increases only slightly, if at all, with increased depth-of-discharge and/or time. 5 Effectively, then, the lithium limited high-rate cell 60E is characterized by a rate capability that exhibits minimal dependence on time or depth-of-discharge throughout a majority of the battery's life. With this characteristic in mind, an IMD incorporating the power source 54F (FIG. 8) including the high-rate cell 60F can be programmed to establish the PLF and ERI values shown in FIG. 10.

10 By way of example, and in accordance with one preferred embodiment, the PLF is established at approximately 2.6 volts and the ERI at 2.65 volts. At these values, the rate capability or charge time curve 132 exhibits minimal dependence upon depth-of-discharge and time. For example, the BOL charge time is approximately 8 seconds, the ERI charge time is approximately 10 seconds, and the PLF charge time is approximately 16 seconds. 15 Following the second voltage plateau 136, the charge time rapidly increases to EOL. However, unlike conventionally balanced cells, the ERI and PLF of the anode limited high-rate cell 60F are relatively close to the EOL (relative to an overall length of the voltage curve 130). Thus, unlike conventionally balanced high-rate cells, the anode limited high-rate cell 60F allows for selection of an ERI value at which rate capability and 20 charge time has minimal dependence upon depth-of-discharge or time, and results in a large portion of the cell's 60F capability being utilized. More particularly, the ERI of the high-rate cell 60F is selected such that at least 40 percent of the cathode is consumed; preferably at least 50 percent; more preferably at least 60 percent; most preferably at least 75 percent. 25

As previously described, with embodiment F (FIG. 8), the high-rate cell 60F and the lower-rate cell 62F need not necessarily be connected in parallel. However, with parallel wiring, the lower-rate cell 62F will effectively recharge the high-rate cell 60F following a transient high power pulse, according to the recharging mechanism previously described. Further, with the parallel configuration, it is preferred that the lower-rate cell 30 62F be designed to have a higher voltage (beyond BOL) than the high-rate cell 60F such that as the cells 60F, 62F are discharged, the high-rate cell 62F will remain nearer its BOL voltage and rate capability through more of the cell's 60F useful life. In an even further

preferred embodiment of configuration F employing a parallel construction, the high-rate cell 60F is a lithium-limited SVO cell and the lower-rate cell 62F is a SVO/CF_x hybrid cathode low-rate cell. This construction provides both of the cells with similar BOL voltages, similar depletion voltages (e.g., greater than 90% depletion at PLF), and the lower-rate cell 62F will have a higher voltage (beyond BOL) than the high-rate cell 60F.

The IMD with dual cell power source of the present invention provides a marked improvement over previous designs. In one embodiment, by connecting a first, high-rate cell and a second, lower-rate cell in parallel to a control circuit and an output circuit, and including a switch to selectively uncouple the high-rate cell and the control circuit, the IMD will efficiently utilize the capacity in both cells independent of charge conditions. Regardless of whether the switch is included, the preferred parallel connection can facilitate the lower-rate cell recharging the high-rate cell following a transient high power pulse depending upon a construction of the high-rate cell. In another alternative embodiment, the dual cells are provided as a single reservoir. In yet another alternative embodiment, the high-rate cell has an anode-limited construction and exhibits a charge time characteristic that has minimal dependence on time or depth-of-discharge. With this configuration, a majority of the high-rate cell's capacity is utilized while satisfying rigorous charge time requirements.

Although the present invention has been described with reference to preferred embodiments, it will be appreciated by those of ordinary skill in the art that a wide variety of alternate and/or equivalent implementations calculated to achieve the same purposes may be substituted for the specific embodiments shown and described without departing from the spirit and scope of the present invention.

WHAT IS CLAIMED IS:

1. An implantable medical device comprising:
 - a hermetic enclosure;
 - a low-power control circuit located in the enclosure;
 - a high-power output circuit located in the enclosure for delivering an electrical pulse therapy; and
 - a power source and circuitry located in the enclosure for powering the low-power control circuit and the high-power output circuit, the power source and circuitry comprising:
 - a first, high-rate cell,
 - a second, lower-rate cell having a rate capability less than a rate capability of the first, high-rate cell,
 - wherein the first cell and second cell are electrically connected in parallel to the low-power control circuit and the high-power output circuit,
 - a switching circuit electrically connected between the first, high-rate cell and the low-power control circuit for selectively uncoupling the first, high-rate cell from the low-power control circuit upon activation of the high-power output circuit.
2. The implantable medical device of claim 1, wherein the switching circuit is configured to uncouple the high-rate cell from the low-power control circuit during a transient high power pulse.
3. The implantable medical device of claim 1, wherein the first, high-rate cell has an electrode surface area greater than an electrode surface area of the second, lower-rate cell.
4. The implantable medical device of claim 1, wherein the first, high-rate cell and the second, lower-rate cell are maintained within a single case.
5. The implantable medical device of claim 4, wherein the case is D-shaped.
6. The implantable medical device of claim 4, wherein the first, high-rate cell is recharged by the second, lower-rate cell.
7. The implantable medical device of claim 6, wherein the first, high-rate cell includes an anode and a cathode, and further wherein the second, lower-rate cell includes a cathode reservoir such that after the first, high-rate cell is discharged, electrons flow from the cathode reservoir to the cathode to re-charge the first, high-rate cell.

8. The implantable medical device of claim 7, wherein the cathode and the cathode reservoir are selected from the group consisting of silver oxide, vanadium oxide, silver vanadium oxide, manganese dioxide, copper oxide, copper silver vanadium oxide, lead oxide, carbon monofluoride, chromium oxide, bismuth-containing oxide, copper sulfate, and mixtures thereof.
9. The implantable medical device of claim 7, wherein the cathode reservoir is a pellet.
10. The implantable medical device of claim 9, wherein the anode and the cathode of the first, high-rate cell are wrapped about the pellet.
11. The implantable medical device of claim 9, wherein the pellet is located apart from the anode and the cathode of the first, high-rate cell.
12. The implantable medical device of claim 7, wherein the second, lower-rate cell further includes an anode associated with the cathode reservoir.
13. The implantable medical device of claim 12, wherein the anode of the first, high-rate cell and the anode of the second, lower-rate cell are formed from lithium.
14. An implantable medical device comprising:
 - a hermetic enclosure;
 - a low-power control circuit located in the enclosure;
 - a high-power output circuit located in the enclosure for delivering an electrical pulse therapy; and
 - a power source located in the enclosure for powering the low-power control circuit and the high-power output circuit, the power source comprising:
 - a case,
 - first anode and cathode bodies disposed within the case and combining to define a first cell,
 - second anode and cathode bodies disposed within the case and combining to define a second cell,
 - an electrolyte contained within the case, wherein the electrolyte commonly activates the first and second cells;

wherein the first and second cells are electrically connected in parallel to the low-power control circuit and the high-power output circuit.

15. The implantable medical device of claim 14, wherein the first cell has an electrode surface area greater than an electrode surface area of the second cell.

16. The implantable medical device of claim 14, wherein the first cell is a high-rate cell and the second cell has a rate capability less than a rate capability of the first cell.

17. The implantable medical device of claim 16, wherein the second cell is a medium-rate cell.

18. The implantable medical device of claim 16, wherein the second cell is a low-rate cell.

19. The implantable medical device of claim 14, wherein the first cell is re-charged by the second cell.

20. The implantable medical device of claim 14, wherein the cathode and the cathode reservoir are selected from the group consisting of silver oxide, vanadium oxide, silver vanadium oxide, manganese dioxide, copper oxide, copper silver vanadium oxide, lead oxide, carbon monofluoride, chromium oxide, bismuth-containing oxide, copper sulfate, and mixtures thereof.

21. The implantable medical device of claim 14, wherein the anodes are formed from lithium.

22. The implantable medical device of claim 14, further including:

a switching circuit electrically connected between the first cell and the low-power control circuit for selectively uncoupling the first cell from the low-power control circuit upon activation of the high-power output circuit.

23. The implantable medical device of claim 14, wherein the first and second cells are connected in parallel internally within the case.

24. The implantable medical device of claim 14, wherein the second cell includes a reservoir pellet, and the first cell is a wound electrode.

25. The implantable medical device of claim 24, wherein the second cell further includes an anode body located adjacent the reservoir pellet.

26. The implantable medical device of claim 24, wherein the first cell is wound about the reservoir pellet.
27. The implantable medical device of claim 24, wherein the first cell is positioned adjacent the reservoir pellet.
28. An implantable medical device comprising:
 - a hermetic enclosure;
 - a circuit located in the enclosure including a low-power control circuit and a high-power output circuit;
 - a power source located in the enclosure for powering the circuit, the power source comprising:
 - a first, high-rate cell,
 - a second, lower-rate cell having a rate capability less than a rate capability of the first, high-rate cell,
 - circuitry electrically connecting the first and second cells in parallel;
 - wherein the first and second cells are separately enclosed and are electrically connected to the circuit such that the first and second cells are not independently dischargeable.
29. The implantable medical device of claim 28, wherein the second, lower-rate cell is a medium-rate cell.
30. The implantable medical device of claim 28, wherein the first, high-rate cell is a thin film electrode.
31. The implantable medical device of claim 30, wherein the first, high-rate cell is positioned below the circuit.
32. The implantable medical device of claim 31, wherein the second, lower-rate cell is positioned adjacent the circuit.
33. The implantable medical device of claim 32, wherein the second, lower-rate cell has a thickness approximately a combined thickness of the circuit and the first high-rate cell.
34. An implantable medical device comprising:
 - a hermetic enclosure;

a low-power control circuit located in the enclosure;

a high-power output circuit located in the enclosure for delivering an electrical pulse therapy; and

a power source located in the enclosure for powering the low-power control circuit and the high-power output circuit, the power source comprising:

a first, high-rate cell including an anode, a cathode, and an electrolyte and characterized by a rate capability exhibiting minimal dependence on time up to a pre-selected voltage-based ERI at which at least 40 percent of the cathode is consumed,

a second, lower-rate cell having a rate capability less than a rate capability of the first, high-rate cell.

35. The implantable medical device of claim 34, wherein the first, high-rate cell is characterized by a rate capability exhibiting minimal dependence upon depth-of-discharge up to the ERI.

36. The implantable medical device of claim 34, wherein at least 75 percent of the cathode is consumed at the ERI.

37. The implantable medical device of claim 34, wherein the first, high-rate cell is an anode-limited cell.

38. The implantable medical device of claim 37, wherein the ERI is approximately 2.65 volts.

39. The implantable medical device of claim 34, wherein the first, high-rate cell is characterized by a charge time of less than approximately 12 seconds at the ERI.

40. The implantable medical device of claim 34, wherein the first, high-rate cell powers the high power control circuit, and further wherein the second, lower-rate cell powers the low-power control circuit.

41. The implantable medical device of claim 34, wherein the second, lower-rate cell is a medium-rate cell.

42. The implantable medical device of claim 34, wherein the second, lower-rate cell is a low-rate cell.

43. The implantable medical device of claim 34, wherein the first, high rate cell is a lithium-limited SVO cell and the second, lower-rate cell is a SVO/CF_x hybrid cathode medium-rate cell.

1/8




Fig. 1

2/8




Fig. 2




Fig. 3

4/8




Fig. 4

5/8




Fig. 5A




Fig. 5B

6/8




Fig. 5C




Fig. 6

7/8




Fig. 7




Fig. 8

8/8




Fig. 9




Fig. 10

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/089904 A3

(51) International Patent Classification⁷: A61N 1/378,
II01M 6/50

Noble Avenue, North, Brooklyn Center, MN 55429 (US).
HOCH, Ronald, F; 3426 South Coon Creek Drive, Brooklyn Center, MN 55429 (US). LESSAR, Joseph, F; 3742 114th Avenue Northwest, Coon Rapids, MN 55433 (US). STROM, James; 3740 McCracken Lane, Arden Hills, MN 55112 (US).

(21) International Application Number: PCT/US02/08889

(22) International Filing Date: 20 March 2002 (20.03.2002)

(25) Filing Language: English

(74) Agents: WOLDE-MICHAEL, Girma, et al.; Medtronic, Inc., 710 Medtronic Parkway LC 340, Minneapolis, MN 55432 (US).

(26) Publication Language: English

(81) Designated States (national): CA, JP.

(30) Priority Data:
09/850,331 7 May 2001 (07.05.2001) US

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SI, TR).

(71) Applicant: MEDTRONIC, INC. [US/US]; 710 Medtronic Parkway LC340, Minneapolis, MN 55432 (US).


(72) Inventors: FARLEY, Mary, A; 3835 Susan Lane, Minnetonka, MN 55305 (US). JOHNSTONE, George; 6442

Published:

— with international search report

[Continued on next page]

(54) Title: IMPLANTABLE MEDICAL DEVICE WITH DUAL CELL POWER SOURCE



WO 02/089904 A3

(57) Abstract: Structures and methods relating to electrodes for incorporation into a feedthrough with a profile adapted for subcutaneous sensing of physiologic and cardiac signals. Electrode assemblies are adapted for integration with feedthrough to enable maximal electrode spacing, minimal myopotential electrical noise and provide reliable insulation from the IMD housing. Various structures and manufacturing processes are implemented to provide a large sensing surface with a low profile. The subcutaneous sensing electrode assembly provides a leadless sensing system and further enhances installation and follow-up procedures.

INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 02/08889

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61N1/378 H01M6/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61N H01M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 05750 A (MAILE KEITH R ;WARREN JAY A (US); CARDIAC PACEMAKERS (US)) 4 February 1999 (1999-02-04) the whole document	14, 16-18, 20,21
Y	---	22
A	---	34-43
Y	US 5 614 331 A (TAKEUCHI ESTHER S ET AL) 25 March 1997 (1997-03-25) cited in the application the whole document	1-5,7,8, 12,13, 28,29
Y	US 6 087 809 A (TAKEUCHI ESTHER S ET AL) 11 July 2000 (2000-07-11) the whole document	1-5,7,8, 12,13, 22,28,29
	---	-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

10 July 2002

Date of mailing of the international search report

17/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ferrigno, A

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No

PCT/US 02/08889

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9905750	A	04-02-1999	EP	1004148 A1	31-05-2000
			WO	9905750 A1	04-02-1999
			US	6238813 B1	29-05-2001
US 5614331	A	25-03-1997	AU	700923 B2	14-01-1999
			AU	7547496 A	26-06-1997
			DE	69602247 D1	02-06-1999
			DE	69602247 T2	23-09-1999
			EP	0780918 A1	25-06-1997
			JP	9199095 A	31-07-1997
US 6087809	A	11-07-2000	US	6008625 A	28-12-1999
			AU	9241998 A	05-08-1999
			EP	0930665 A2	21-07-1999
			JP	11283679 A	15-10-1999
US 6044295	A	28-03-2000	EP	0872261 A2	21-10-1998
US 5372605	A	13-12-1994	US	5235979 A	17-08-1993
			US	5439482 A	08-08-1995
			DE	69311113 D1	03-07-1997
			DE	69311113 T2	11-12-1997
			EP	0650383 A1	03-05-1995
			EP	0771576 A2	07-05-1997
			WO	9402202 A1	03-02-1994
			US	5405363 A	11-04-1995
			US	5827326 A	27-10-1998